Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis
Novo released new evidence that its experimental CagriSema injection can improve upon the weight loss with its blockbuster GLP-1 obesity injection, Wegovy.
Novo released new evidence that its experimental CagriSema injection can improve upon the weight loss with its blockbuster GLP-1 obesity injection, Wegovy. This story matters for Finance & Markets readers tracking currency. Reported by cnbc.com. Read the full original at the source link below.
Originally reported by cnbc.com. CurrencyNews.com curates and briefs the finance & markets stories that matter. Our editorial policy →
Get the daily currency signal